BlackThorn: BlackThorn Therapeutics Reports Data Supporting Phase 2 Development of KOR Antagonist, BTRX-335140, in Depression and Other CNS Disorders
Press release content from Business Wire. The AP news staff was not involved in its creation.
Read full article »
BlackThorn is a biopharmaceutical company that discovers and develops novel targeted therapeutics for the treatment of neurobehavioral disorders.
Read more